Understanding the Genetic Basis of Familial Combined Hyperlipidemia in Mexican Individuals
Familial combined hyperlipidemia (FCHL) is an inherited disorder characterized by elevated levels of cholesterol and triglycerides; it often occurs in Mexican individuals with coronary heart disease (CHD). The purpose of this study is to identify the specific genes that predispose Mexican individuals to FCHL.
Hyperlipidemia, Familial Combined
|Study Design:||Observational Model: Family-Based
Time Perspective: Cross-Sectional
|Official Title:||Genetic Susceptibility to Common Lipid Disorders in Mexico|
- Identifying the specific genes that predispose Mexican individuals to FCHL [ Time Frame: Measured through the use of genetic samples ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples With DNA
Whole blood sample is taken from all participants and adipose tissue sample from a subgroup.
|Study Start Date:||July 2006|
|Study Completion Date:||June 2011|
|Primary Completion Date:||June 2011 (Final data collection date for primary outcome measure)|
CHD is the leading cause of death in Mexico. Dyslipidemia that is characterized by high total cholesterol, high triglycerides, and low "good" high-density lipoprotein (HDL) cholesterol is a risk factor for developing CHD. Research has shown that the Mexican population has an increased tendency towards dyslipidemia, but it is not known what genetic factors contribute to this predisposition. This study will examine the genetic basis of FCHL, which is an inherited form of dyslipidemia characterized by elevated levels of total cholesterol and triglycerides. FCHL is a major contributing factor in CHD; 20% of individuals with CHD under the age of 60 have FCHL. The purpose of this study is to identify and characterize the specific DNA sequence variations that predispose Mexican individuals to FCHL. Results of this study may aid in the development of appropriate prevention and screening techniques.
This study will enroll individuals in Mexico who have FCHL. Participants will attend one study visit for blood collection and DNA sampling. Family members of participants will be contacted and asked to provide a DNA sample also. A select group of participants will return for a second study visit for RNA sampling. Study researchers will analyze participants' DNA and RNA samples, as well as two FCHL genes identified in previous research studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00365235
|Instituto Nacional De Ciencias Medicas y Nutricion|
|Mexico City, Mexico, 14000|
|Principal Investigator:||Paivi E. Pajukanta, MD, PhD||David Geffen School of Medicine at UCLA, Department of Human Genetics|